The tumour suppressor CYLD negatively regulates NF-κB signalling by deubiquitination (original) (raw)

Nature volume 424, pages 801–805 (2003)Cite this article

Abstract

NF-κB transcription factors have key roles in inflammation, immune response, oncogenesis and protection against apoptosis1,2. In most cells, these factors are kept inactive in the cytoplasm through association with IκB inhibitors. After stimulation by various reagents, IκB is phosphorylated by the IκB kinase (IKK) complex3 and degraded by the proteasome, allowing NF-κB to translocate to the nucleus and activate its target genes. Here we report that CYLD, a tumour suppressor that is mutated in familial cylindromatosis4, interacts with NEMO, the regulatory subunit of IKK5,6. CYLD also interacts directly with tumour-necrosis factor receptor (TNFR)-associated factor 2 (TRAF2), an adaptor molecule involved in signalling by members of the family of TNF/nerve growth factor receptors. CYLD has deubiquitinating activity that is directed towards non-K48-linked polyubiquitin chains, and negatively modulates TRAF-mediated activation of IKK, strengthening the notion that ubiquitination is involved in IKK activation by TRAFs and suggesting that CYLD functions in this process. Truncations of CYLD found in cylindromatosis result in reduced enzymatic activity, indicating a link between impaired deubiquitination of CYLD substrates and human pathophysiology.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 51 print issues and online access

$199.00 per year

only $3.90 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

References

  1. Karin, M. & Ben-Neriah, B. Phosphorylation meets ubiquitination: the control of NF-κB activity. Annu. Rev. Immunol. 18, 621–663 (2000)
    Article CAS Google Scholar
  2. Li, Q. & Verma, I. M. NF-κB regulation in the immune system. Nature Rev. Immunol. 2, 725–734 (2002)
    Article CAS Google Scholar
  3. Israël, A. The IKK complex: an integrator of all signals that activate NF-κB? Trends Cell. Biol. 10, 129–133 (2000)
    Article Google Scholar
  4. Bignell, G. R. et al. Identification of the familial cylindromatosis tumour-suppressor gene. Nature Genet. 25, 160–165 (2000)
    Article CAS Google Scholar
  5. Yamaoka, S. et al. Complementation cloning of NEMO, a component of the IκB kinase complex essential for NF-κB activation. Cell 93, 1231–1240 (1998)
    Article CAS Google Scholar
  6. Rothwarf, D. M., Zandi, E., Natoli, G. & Karin, M. IKK-γ is an essential regulatory subunit of the IκB kinase complex. Nature 395, 297–300 (1998)
    Article ADS CAS Google Scholar
  7. Courtois, G., Smahi, A. & Israël, A. NEMO/IKKγ: linking NF-κB to human disease. Trends Mol. Med. 7, 427–430 (2001)
    Article CAS Google Scholar
  8. Ye, H., Park, Y. C., Kreishman, M., Kieff, E. & Wu, H. The structural basis for the recognition of diverse receptor sequences by TRAF2. Mol. Cell 4, 321–330 (1999)
    Article CAS Google Scholar
  9. Wilkinson, K. D. Regulation of ubiquitin-dependent processes by deubiquitinating enzymes. FASEB J. 11, 1245–1256 (1997)
    Article CAS Google Scholar
  10. D'Andrea, A. & Pellman, D. Deubiquitinating enzymes: a new class of biological regulators. Crit. Rev. Biochem. Mol. Biol. 33, 337–352 (1998)
    Article CAS Google Scholar
  11. Deng, L. et al. Activation of the IκB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 103, 351–361 (2000)
    Article CAS Google Scholar
  12. Wang, C. et al. TAK1 is a ubiquitin-dependent kinase of MKK and IKK. Nature 412, 346–351 (2001)
    Article ADS CAS Google Scholar
  13. Shi, C. S. & Kehrl, J. H. TNF-induced GCKR and SAPK activation depends upon the E2/E3 complex Ubc13–Uev1A/TRAF2. J. Biol. Chem. 278, 15429–15434 (2003)
    Article CAS Google Scholar
  14. Maniatis, T. A ubiquitin ligase complex essential for the NF-κB, Wnt/Wingless, and Hedgehog signaling pathways. Genes Dev. 13, 505–510 (1999)
    Article CAS Google Scholar
  15. Pomerantz, J. L. & Baltimore, D. Two pathways to NF-κB. Mol. Cell 10, 693–695 (2002)
    Article CAS Google Scholar
  16. Chu, Z. L., DiDonato, J. A., Hawiger, J. & Ballard, D. W. The tax oncoprotein of human T-cell leukemia virus type 1 associates with and persistently activates IκB kinases containing IKKα and IKKβ. J. Biol. Chem. 273, 15891–15894 (1998)
    Article CAS Google Scholar
  17. Mercurio, F. et al. IKK-1 and IKK-2: cytokine-activated IκB kinases essential for NF-κB activation. Science 278, 860–866 (1997)
    Article ADS CAS Google Scholar
  18. McManus, M. T. & Sharp, P. A. Gene silencing in mammals by small interfering RNAs. Nature Rev. Genet. 3, 737–747 (2002)
    Article CAS Google Scholar
  19. Brummelkamp, T. R., Bernards, R. & Agami, R. A system for stable expression of short interfering RNAs in mammalian cells. Science 296, 550–553 (2002)
    Article ADS CAS Google Scholar
  20. Borodovsky, A. et al. Chemistry-based functional proteomics reveals novel members of the deubiquitinating enzyme family. Chem. Biol. 9, 1149–1159 (2002)
    Article CAS Google Scholar
  21. Karin, M., Cao, Y., Greten, F. R. & Li, Z. W. NF-κB in cancer: from innocent bystander to major culprit. Nature Rev. Cancer 2, 301–310 (2002)
    Article CAS Google Scholar
  22. Döffinger, R. et al. X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-κB signaling. Nature Genet. 27, 277–85 (2001)
    Article Google Scholar

Download references

Acknowledgements

We thank R. Agami for the pSUPER vector and advice; R. Beyaert, C. J. Kirschning, M. Krönke, F. Mercurio, K.-I. Nakayama, M. Rowe and M. Treier for plasmids; T. Goncharov, S. Leu, D. Landstein, M. Pasparakis, F. Agou and S. Yamaoka for discussions and support; and I. Beilis and T. Lopez for technical assistance. This work was supported in part by grants from Inter-Lab Ltd, from Ares Trading SA and from the Alfred and Ann Goldstein Foundation to A.K., G.Ca amd D.W., from PTR Pasteur/Necker to G.Co, and from ‘La ligue Nationale contre le Cancer’ (équipe labellisée) to A.I. A.K. was supported by a postdoctoral fellowship from ‘La ligue Nationale contre le Cancer’.

Author information

Authors and Affiliations

  1. Department of Biological Chemistry, The Weizmann Institute of Science, 76100, Rehovot, Israel
    Andrew Kovalenko, Giuseppina Cantarella & David Wallach
  2. Unité de Biologie Moléculaire de l'Expression Génique, CNRS URA 2582, Institut Pasteur, 75015, Paris, France
    Andrew Kovalenko, Christine Chable-Bessia, Alain Israël & Gilles Courtois
  3. Department of Experimental and Clinical Pharmacology, University of Catania School of Medicine, I-95125, Catania, Italy
    Giuseppina Cantarella

Authors

  1. Andrew Kovalenko
    You can also search for this author inPubMed Google Scholar
  2. Christine Chable-Bessia
    You can also search for this author inPubMed Google Scholar
  3. Giuseppina Cantarella
    You can also search for this author inPubMed Google Scholar
  4. Alain Israël
    You can also search for this author inPubMed Google Scholar
  5. David Wallach
    You can also search for this author inPubMed Google Scholar
  6. Gilles Courtois
    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence toDavid Wallach.

Ethics declarations

Competing interests

The authors declare that they have no competing financial interests.

Supplementary information

Rights and permissions

About this article

Cite this article

Kovalenko, A., Chable-Bessia, C., Cantarella, G. et al. The tumour suppressor CYLD negatively regulates NF-κB signalling by deubiquitination.Nature 424, 801–805 (2003). https://doi.org/10.1038/nature01802

Download citation

This article is cited by